Maughan, Benjamin L <br/><br/>
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Dec 2016 
 - 1297-1304 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-016-3191-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anilides--adverse effects<br/>Hedgehog Proteins--antagonists & inhibitors<br/>Humans<br/>Male<br/>Middle Aged<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms, Castration-Resistant--blood<br/>Pyridines--adverse effects<br/>Zinc Finger Protein GLI1--genetics